Bionomics (BNO) Stock Price, News & Analysis

Company Overview

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 386,458 shs
• Average Volume: N/A
• Market Capitalization: A$13.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BNO Stock Analysis - Frequently Asked Questions

How were Bionomics' earnings last quarter?

Bionomics Limited (ASX:BNO) posted its earnings results on Friday, February, 15th. The company reported ($0.02) EPS for the quarter. Bionomics had a negative trailing twelve-month return on equity of 116.12% and a negative net margin of 14,558.34%.

What other stocks do shareholders of Bionomics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bionomics investors own include McDermott International (MDR), Pacific Drilling (PACDQ), OreCorp (ORR), ORBCOMM (ORBC), Lithium Power International (LPI), Lithium Australia (LIT) and CocaCola (KO).

Company Calendar

• Last Earnings: 2/15/2019
• Today: 7/05/2025

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:BNO
• CIK: N/A
• Web: www.bionomics.com.au
• Phone: +61-8-83546100
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$24.91 million
• Net Margins: -14,558.34%
• Pretax Margin: N/A
• Return on Equity: -116.12%
• Return on Assets: -20.98%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 3.30
• Quick Ratio: 12.02

Sales & Book Value

• Annual Sales: A$6.02 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 2.69
• Book Value: A$1.09 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,470,000,000
• Free Float: N/A
• Market Cap: A$13.22 million
• Optionable: Not Optionable
• Beta: 2.13